Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase IV Studies Encounter Delays, Yield Mixed Data – Tufts Report

Executive Summary

A survey of 61 post-marketing drug studies conducted by the Tufts Center for the Study of Drug Development concluded that almost half of those trials did not meet their projected completion date. The center released results of the report, which appears in the May/June Tufts CSDD Impact Report, May 15
Advertisement

Related Content

FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines
PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
Advertisement
UsernamePublicRestriction

Register

PS048388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel